Localization and Suppression of a Kinetic Defect in Cystic Fibrosis Transmembrane Conductance Regulator Folding*
- From the Department of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas 75235-9040
Abstract
A growing body of evidence indicates that the most common cystic fibrosis-causing mutation, ΔF508, alters the ability of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to fold and transit to the plasma membrane. Here we present evidence that the ΔF508 mutation affects a step on the folding pathway prior to formation of the ATP binding site in the nucleotide binding domain (NBD). Notably, stabilization of the native state with 4 mm ATP does not alter the temperature-dependent folding yield of the mutant ΔF508 NBD1 in vitro. In contrast, glycerol, which promotes ΔF508-CFTR maturation in vivo, increases the folding yield of NBD1ΔF and reduces the off pathway rate in vitro, although it does not significantly alter the free energy of stability. Likewise a second site mutation, R553M, which corrects the maturation defect in vivo, is a superfolder which counters the effects of ΔF508 on the temperature-dependent folding yield in vitro, but does not significantly alter the free energy of stability. A disease-causing mutation, G551D, which does not alter the maturation of CFTR in vivo but rather its function as a chloride channel, and the S549R maturation mutation have no discernible effect on the folding of the domain. These results demonstrate that ΔF508 is a kinetic folding mutation that affects a step early in the process, and that there is a significant energy barrier between the native state and the step affected by the mutation precluding the use of native state ligands to promote folding. The implications for protein folding in general are that the primary sequence may not necessarily simply define the most stable native structure, but rather a stable structure that is kinetically accessible.
Footnotes
-
↵* This work was supported by National Institutes of Health Grant DK49835 and Welch Foundation Grant I-1284.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
↵‡ To whom correspondence should be addressed: Dept. of Physiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75235-9040. Tel: 214-648-8723; Fax: 214-648-8685; E-mail: thomas07{at}utsw.swmed.edu.
-
↵1 The abbreviations used are: CF, cystic fibrosis; CFTR, CF transmembrane conductance regulator; NBD1, amino-terminal nucleotide binding domain; GdnHCl, guanidine hydrochloride; Tricine,N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine.
-
- Received December 17, 1996.
- Revision received March 18, 1997.











